
CLAIMS

WHAT IS CLAIMED IS:

1. A formulation comprising:

(a) a compound of the formula:



I-1,

or a pharmaceutically-acceptable salt thereof; dissolved in

(b) a substantially anhydrous solvent comprising about 45% to about 85% propylene glycol; about 5% to about 45% glycerin; and 0% to about 30% ethanol.

2. The formulation of claim 1, wherein said solvent comprises about 65% to about 70% propylene glycol; about 25% to about 30% glycerin, and 0% to about 10% ethanol.

3. The formulation of claim 1, wherein said solvent comprises 65% to 70% propylene glycol and 25% to 30% glycerin, any balance being ethanol.

4. The formulation of claim 1, wherein said solvent comprises about 65% propylene glycol; about 25% glycerin; and about 10% ethanol.

5. The formulation of claim 4, wherein said solvent is 65% propylene glycol; 25% glycerin;

and 10% ethanol.

6. The formulation of claim 2, wherein said solvent comprises about 70% propylene glycol and about 30% glycerin, ethanol being absent.

7. The formulation of claim 1, wherein said solvent comprises:

(a) 45% to 85% propylene glycol; 5% to 45% glycerin; and 0% to 30% ethanol; or
(b) 65% to 70% propylene glycol; 25% to 30% glycerin, and 0% to 10% ethanol.

8. The formulation of any one of the preceding claims, wherein said salt is a sodium salt.

9. The formulation of any one of the preceding claims, wherein the compound is present at a concentration of about 80 mg/mL to about 110 mg/mL, optionally about 100 mg/mL.

10. The formulation of any one of the preceding claims, further comprising DMSO, optionally at a DMSO:compound ratio of about 2: about 1; about 1: about 1; about 0.5: about 1; about 0.3: about 1; or about 0.2 - about 0.3: about 1.

11. The formulation of any one of the preceding claims, suitable for administration by subcutaneous injection.

12. A kit comprising:

(a) a first vessel containing a compound as defined in claim 1 or claim 8;
(b) a second vessel containing a substantially anhydrous solvent as defined in any one of claims 1-7.

13. The kit of claim 12, wherein the compound is in the form of a substantially anhydrous powder.

14. The kit of claim 13, wherein the compound is lyophilized.

15. The kit of any one of claims 12-14, wherein the first vessel contains about 80 mg to

about 110 mg of said compound.

16. The kit of any one of claims 12-15, wherein the first vessel contains about 100 mg of said compound.

17. The kit of any one of claims 12-16, further comprising instructions for administration by subcutaneous injection.


18. A process for preparing a pharmaceutical composition comprising dissolving a compound as defined in claim 1 or claim 8 in a substantially anhydrous solvent as defined in any one of claims 1-7.

19. The process of claim 18, further comprising the steps of:

(a) dissolving said compound in DMSO to produce a solution of said compound in DMSO; and

(b) lyophilizing said solution of step (a) to provide said compound as a substantially anhydrous powder.

20. A process for producing a compound of the formula:



I-1

or a pharmaceutically-acceptable salt thereof, in the form of a substantially anhydrous

powder, the process comprising dissolving said compound or salt thereof in DMSO to produce a solution in DMSO, and then lyophilizing said solution to provide said compound or salt thereof as a substantially anhydrous powder.


21. The process of claim 20, wherein said substantially anhydrous powder comprises residual DMSO.

22. The process of claim 21, wherein said residual DMSO is present in an amount of up to about 2000 mg/g of said compound of formula I-1.

23. The process of claim 22, wherein said residual DMSO is present in an amount of up to about 1000mg/g; up to about 600mg/g; up to about 500mg/g; up to about 400mg/g; up to about 300mg/g or about 200 – about 300mg/g of said compound of formula I-1.

24. The process of claim 23, wherein said residual DMSO is present in an amount of about 200 – about 300 mg/g of said compound of formula I-1.

25. A substantially anhydrous powder consisting essentially of a compound of the formula:



I-1

or a pharmaceutically-acceptable salt thereof, and DMSO, the DMSO being present in an amount of up to about 200 % w/w .

26. The powder of claim 25, wherein the DMSO is present in an amount of up to about 100%, up to about 60%, up to about 50%, up to about 40% or up to about 30% w/w DMSO/compound of formula I-1.

27. The powder of claim 26, wherein the DMSO is present in an amount of about 20 – about 30% w/w DMSO/compound of formula I-1.

28. The process of any one of claims 18-24 or powder of any one of claims 25-27, wherein said salt is a sodium salt.

29. A pharmaceutical composition obtainable by the process of any one of claims 18- 24 or claim 28.

30. A method for treating a cancer, myelodysplastic syndrome, leukemia or solid tumour comprising administering the formulation of any one of claims 1-11, kit of any one of claims 12-17, powder of any one of claims 25-27 or composition of claim 29 to a subject in need or want thereof.

31. The formulation of any one of claims 1-11, kit of any one of claims 12-17, powder of any one of claims 25-27 or composition of claim 29 for use in a method of treating a cancer, myelodysplastic syndrome, leukemia or solid tumour, said method comprising administering said formulation or composition to a subject.

32. Use of the formulation of any one of claims 1-11, kit of any one of claims 12-17, powder of any one of claims 25-27 or composition of claim 29 for the manufacture of a medicament for use in a method of treating a cancer, myelodysplastic syndrome, leukemia or solid tumour, said method comprising administering said formulation or composition to a subject.


33. The method, formulation, composition, kit, powder or use of any one of claims 30-32 wherein said method comprises treating a disease selected from those described herein.

34. The method, formulation, composition, kit, powder or use of any one of claims 30-33 wherein the administration is subcutaneous administration.

CLAIMS:

1. A formulation comprising:

(a) a compound of the formula:



I-1,

or a pharmaceutically-acceptable salt thereof; dissolved in

(b) a substantially anhydrous solvent comprising about 60% to 70% propylene glycol; about 20% to 30% glycerin; and about 5% to 15% ethanol (w/w/w).

2. The formulation of claim 1, wherein said solvent comprises 60% to 70% propylene glycol; 20% to 30% glycerin; and 5% to 15% ethanol (w/w/w).

3. The formulation of claim 1, wherein said solvent consists essentially of about 60% to 70% propylene glycol; about 20% to 30% glycerin; and about 5% to 15% ethanol (w/w/w).

4. The formulation of claim 1, wherein said solvent consists essentially of 60% to 70% propylene glycol; 20% to 30% glycerin; and 5% to 15% ethanol (w/w/w).

5. The formulation of claim 1, wherein said solvent is about 60% to 70% propylene glycol; about 20% to 30% glycerin; and about 5% to 15% ethanol (w/w/w).

6. The formulation of claim 1, wherein said solvent is 60% to 70% propylene glycol; 20% to 30% glycerin; and 5% to 15% ethanol (w/w/w).

7. The formulation of claim 1, wherein said solvent comprises about 65% propylene glycol; about 25% glycerin; and about 10% ethanol (w/w/w).

8. The formulation of claim 1, wherein said solvent comprises 65% propylene glycol; 25% glycerin; and 10% ethanol (w/w/w).

9. The formulation of claim 1, wherein said solvent consists essentially of about 65% propylene glycol; about 25% glycerin; and about 10% ethanol (w/w/w).

10. The formulation of claim 1, wherein said solvent consists essentially of 65% propylene glycol; 25% glycerin; and 10% ethanol (w/w/w).

11. The formulation of claim 1, wherein said solvent is about 65% propylene glycol; about 25% glycerin; and about 10% ethanol (w/w/w).

12. The formulation of claim 1, wherein said solvent is 65% propylene glycol; 25% glycerin; and 10% ethanol (w/w/w).

13. The formulation of any one of the preceding claims, wherein said salt is a sodium salt.

14. The formulation of any one of the preceding claims, wherein the compound is present at a concentration of about 80 mg/mL to about 110 mg/mL, optionally about 100 mg/mL.

15. The formulation of any one of the preceding claims, further comprising DMSO, optionally at a DMSO:compound ratio of about 2: about 1; about 1: about 1; about 0.5: about 1; about 0.3: about 1; or about 0.2 - about 0.3: about 1.

16. The formulation of any one of the preceding claims, suitable for administration by subcutaneous injection.

17. A kit comprising:

(a) a first vessel containing a compound as defined in claim 1 or claim 13;
(b) a second vessel containing a substantially anhydrous solvent as defined in any one of claims 1-12.

18. The kit of claim 17, wherein the compound is in the form of a substantially anhydrous powder.

19. The kit of claim 18, wherein the compound is lyophilized.

20. The kit of any one of claims 17-19, wherein the first vessel contains about 80 mg to about 110 mg of said compound.

21. The kit of any one of claims 17-20, wherein the first vessel contains about 100 mg of said compound.

22. The kit of any one of claims 17-21, further comprising instructions for administration by subcutaneous injection.

23. The kit of any one of claims 18-22 wherein the substantially anhydrous powder consists essentially of said compound and DMSO, the DMSO being present in an amount of up to about 200 % w/w.

24. The kit of claim 23, wherein the DMSO is present in an amount of up to about 100%, up to about 60%, up to about 50%, up to about 40% or up to about 30% w/w DMSO/compound.

25. The kit of claim 24, wherein the DMSO is present in an amount of about 20 – about 30% w/w DMSO/compound.

26. A process for preparing a pharmaceutical composition comprising dissolving a compound as defined in claim 1 or claim 13 or a substantially anhydrous powder as defined in claims 18 and 23-25 in a substantially anhydrous solvent as defined in any one of claims 1-12.

27. The process of claim 26, further comprising the steps of:

(a) dissolving said compound in DMSO to produce a solution of said compound in DMSO; and

(b) lyophilizing said solution of step (a) to provide said compound as a substantially anhydrous powder.

28. A pharmaceutical composition obtainable by the process of claim 26 or claim 27.

29. The formulation of any one of claims 1-16, kit of any one of claims 17-25, or composition of claim 28 for use in treating a cancer, myelodysplastic syndrome, leukemia or solid tumour, wherein said formulation or composition is to be administered to a subject.

30. Use of the formulation of any one of claims 1-16, kit of any one of claims 17-25, or composition of claim 28 for the manufacture of a medicament for treating a cancer, myelodysplastic syndrome, leukemia or solid tumour, wherein said medicament is to be administered to a subject.

31. The formulation, composition, kit, or use of claim 29 or 30 wherein the administration is subcutaneous administration.